Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued on Tuesday, StockRatingsNetwork reports. They currently have a $43.00 target price on the stock. Zacks‘ price objective points to a potential upside of 5.94% from the company’s current price.
Zacks‘ analyst wrote, “Teva’s first quarter earnings of $1.12 per ADS were a couple of cents above the Zacks Consensus Estimate but 23.8% below the year-ago earnings. First quarter revenues declined 3.9% to $4.9 billion, just above the Zacks Consensus Estimate of $4.8 billion. Teva is going through a transition period. Headwinds include EU pricing pressure, potential new competition for branded products (especially Copaxone) and fewer generic product launches compared to 2012. With the company not including the impact of its cost-savings plan in its 2013 guidance, we believe Teva has left some room for delivering above expectations. Share buybacks also leave some room for upside. We remain Neutral on the stock. We expect investor focus to remain on the execution of the company’s new strategy.”
A number of other firms have also recently commented on TEVA. Analysts at TheStreet reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Monday, July 15th. Finally, analysts at Maxim Group reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Wednesday, June 19th. They now have a $56.00 price target on the stock.
Eleven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $46.38.
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) traded up 1.82% during mid-day trading on Tuesday, hitting $41.33. Teva Pharmaceutical Industries Ltd has a one year low of $36.63 and a one year high of $42.83. The stock’s 50-day moving average is currently $39.16. The company has a market cap of $35.213 billion and a P/E ratio of 20.26.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.02. The company had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.85 billion. During the same quarter last year, the company posted $1.47 earnings per share. Teva Pharmaceutical Industries Ltd’s revenue was down 3.9% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Ltd will post $5.01 EPS for the current fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) is a global pharmaceutical and drug company.
To view Zacks’ full report, visit www.zacks.com